-
Mashup Score: 0Apellis stops dosing of pegcetacoplan in ALS trial after data... - 12 month(s) ago
Apellis stopped treatment with pegcetacoplan in its MERIDIAN trial for ALS after a data review failed to support the study’s continuation.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 0US Senate caucus for ALS eyes awareness, policies, research | ALS... - 12 month(s) ago
The U.S. Senate ALS Caucus was re-established to heighten ALS awareness, advance ALS policies, and advocate for research investments.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
The U.S. Senate ALS Caucus was re-established to heighten ALS awareness, advance ALS policies, and advocate for research investments. https://t.co/0ygxe69E7L
-
-
Mashup Score: 0ALS costs may reach $1.02B each year in US, study finds | ALS... - 1 year(s) ago
It’s estimated there are up to 18,000 people living with ALS in the U.S., with national costs likely to reach $1.02 billion each year.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
The prob w studies that are lit reviews is that if a study gets something wrong, we propagate the myths of ALS Land. 18K is just wrong. It’s estimated there are up to 18,000 people living w ALS in the US, with natl costs likely to reach $1.02 B annually https://t.co/UGe3tIb3L7
-
-
Mashup Score: 0
A wearable robotic device that helps lift the shoulders to support arm movement can make daily tasks easier for ALS patients, a study found.
Source: ALS News TodayCategories: Future of Medicine, Latest HeadlinesTweet-
Wearable robotic device improves arm function for people with ALS... https://t.co/iAZX8JA4LM https://t.co/bFItLXygca
-
-
Mashup Score: 0
NEALS and the ALS Association Greater Philadelphia Chapter will use the $20,000 Cytokinetics’ award to broaden outreach, awareness efforts.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
NEALS and the ALS Association Greater Philadelphia Chapter will use the $20,000 Cytokinetics' award to broaden outreach, awareness efforts. https://t.co/2swN4I6voT
-
-
Mashup Score: 0
Utreloxastat, an investigational therapy for ALS, was safe and displayed promising pharmacological properties in study of healthy people.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
Utreloxastat, an investigational therapy for ALS, was safe and displayed promising pharmacological properties in study of healthy people. https://t.co/lwzHL7N2lb
-
-
Mashup Score: 0
Legislatures can put more money toward ALS programs, and scientists can better link ALS to risk factors with state ALS registries.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
There is a lot in this article that is just wrong. MA had a registry before Gov C dx. Concern was a cluster that did not pan out. Post Gov C funding was better. 1/ https://t.co/oAPkZ0pitu
-
-
Mashup Score: 0
A patient’s genetic information, clinical measurements, and biomarkers can offer insights into ALS and make clinical trials more efficient.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
I wish some "unattached" information scientists from business would take an objective look at ALS Land. It's not as peachy in the data department as this article makes it sound. https://t.co/EJ60QF4BGb
-
-
Mashup Score: 0
DNL343 can enter the brain and reduce the cellular stress response that contributes to disease progression, ALS clinical trial analysis shows
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
DNL343 can enter the brain and reduce the cellular stress response that contributes to disease progression, ALS clinical trial analysis shows https://t.co/UeZUXfYgGb
-
-
Mashup Score: 0Trial of BIIB105 Enrolling ALS Patients With or Without ATXN2... - 1 year(s) ago
Phase 1/2 trial, recruiting ALS adults with or without ATXN2 mutations, aims to see if BIIB105 affects TDP-42 by targeting ataxin-2 protein.
Source: ALS News TodayCategories: Latest Headlines, Rare DiseaseTweet-
Phase 1/2 trial, recruiting ALS adults with or without ATXN2 mutations, aims to see if BIIB105 affects TDP-42 by targeting ataxin-2 protein. https://t.co/6TyOJoTHdn
-
Apellis stopped treatment with pegcetacoplan in its MERIDIAN trial for ALS after a data review failed to support the study's continuation. https://t.co/FNQlzdXC6h